1. Clinicopathological significance of loss of heterozygosity and microsatellite instability in hepatocellular carcinoma in China
   Shu-Hui Zhang, 2005, World Journal of Gastroenterology CrossRef
2. Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy
   Yuqing He et al, 2021, Frontiers in Oncology CrossRef
3. Protein profiles reveal MSH6/MSH2 as a potential biomarker for hepatocellular carcinoma with microvascular invasion
   Shengqian Hong et al, 2024, Hepatology Research CrossRef
4. The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma
   Ambreen Muhammed et al, 2021, Cancers CrossRef
5. DNA methylation alterations of ADCY5, MICAL2, and PLEKHG2 during the developmental stage of cryptogenic hepatocellular carcinoma
   Satomi Makiuchi et al, 2024, Hepatology Research CrossRef
6. A Dose-Dependent Decrease in the Fraction of Cases Harboring M6P/IGF2R Mutations in Hepatocellular Carcinomas from the Atomic Bomb Survivors
   Keisuke S. Iwamoto et al, 2006, Radiation Research CrossRef